ProStrakan CEO quits amid further Sancuso and Abstral woes
This article was originally published in Scrip
ProStrakan's chief executive and director Dr Wilson Totten has resigned after the company revealed it expects to suffer up to £5 million in missed operating profit for the full year as a result of not meeting supply demands for Sancuso (granisetron), a transdermal patch for the prevention of chemotherapy-induced nausea and vomiting.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.